…report also has important implications for drug development and future clinical management of patients with CKD. Previously, we reported that delivery of a pan-FGFR inhibitor could prevent development
C
of LVH and reverse established LVH in rats with CKD (Di Marco et al., 2014; Faul et al., 2011).